-
1
-
-
40549145214
-
Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects
-
DOI 10.1111/j.1365-2125.2007.03084.x
-
Andrews, E., et al. 2008. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. Br. J. Clin. Pharmacol. 65:531-539. (Pubitemid 351365140)
-
(2008)
British Journal of Clinical Pharmacology
, vol.65
, Issue.4
, pp. 531-539
-
-
Andrews, E.1
Damle, B.D.2
Fang, A.3
Foster, G.4
Crownover, P.5
LaBadie, R.6
Glue, P.7
-
2
-
-
0031666585
-
In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species
-
DOI 10.1007/s100960050133
-
Clancy, C. J., and M. H. Nguyen. 1998. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur. J. Clin. Microbiol. Infect. Dis. 17:573-575. (Pubitemid 28464363)
-
(1998)
European Journal of Clinical Microbiology and Infectious Diseases
, vol.17
, Issue.8
, pp. 573-575
-
-
Clancy, C.J.1
Nguyen, M.H.2
-
3
-
-
0036498964
-
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
-
DOI 10.1086/324620
-
Denning, D. W., et al. 2002. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34:563-571. (Pubitemid 34165316)
-
(2002)
Clinical Infectious Diseases
, vol.34
, Issue.5
, pp. 563-571
-
-
Denning, D.W.1
Ribaud, P.2
Milpied, N.3
Caillot, D.4
Herbrecht, R.5
Thiel, E.6
Haas, A.7
Ruhnke, M.8
Lode, H.9
-
4
-
-
0031974507
-
In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
-
Espinel-Ingroff, A. 1998. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36:198-202. (Pubitemid 28047458)
-
(1998)
Journal of Clinical Microbiology
, vol.36
, Issue.1
, pp. 198-202
-
-
Espinel-Ingroff, A.1
-
5
-
-
0034944963
-
In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literature
-
DOI 10.1023/A:1010954803886
-
Espinel-Ingroff, A., K. Boyle, and D. J. Sheehan. 2001. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 150:101-115. (Pubitemid 32623880)
-
(2001)
Mycopathologia
, vol.150
, Issue.3
, pp. 101-115
-
-
Espinel-Ingroff, A.1
Boyle, K.2
Sheehan, D.3
-
6
-
-
0037043655
-
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
-
DOI 10.1056/NEJMoa020191
-
Herbrecht, R., et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415. (Pubitemid 34851833)
-
(2002)
New England Journal of Medicine
, vol.347
, Issue.6
, pp. 408-415
-
-
Herbrecht, R.1
Denning, D.W.2
Patterson, T.F.3
Bennett, J.E.4
Greene, R.E.5
Oestmann, J.-W.6
Kern, W.V.7
Marr, K.A.8
Ribaud, P.9
Lortholary, O.10
Sylvester, R.11
Rubin, R.H.12
Wingard, J.R.13
Stark, P.14
Durand, C.15
Caillot, D.16
Thiel, E.17
Chandrasekar, P.H.18
Hodges, M.R.19
Schlamm, H.T.20
Troke, P.F.21
De Pauw, B.22
more..
-
7
-
-
62949105433
-
Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies
-
Karlsson, M. O., I. Lutsar, and P. A. Milligan. 2009. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob. Agents Chemother. 53:935-944.
-
(2009)
Antimicrob. Agents Chemother.
, vol.53
, pp. 935-944
-
-
Karlsson, M.O.1
Lutsar, I.2
Milligan, P.A.3
-
8
-
-
77955403893
-
Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients
-
Michael, C., et al. 2010. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob. Agents Chemother. 54:3225-3232.
-
(2010)
Antimicrob. Agents Chemother.
, vol.54
, pp. 3225-3232
-
-
Michael, C.1
-
9
-
-
72049130592
-
Voriconazole pharmacokinetics and pharmacodynamics in children
-
Neely, M., T. Rushing, A. Kovacs, R. Jelliffe, and J. Hoffman. 2010. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin. Infect. Dis. 50:27-36.
-
(2010)
Clin. Infect. Dis.
, vol.50
, pp. 27-36
-
-
Neely, M.1
Rushing, T.2
Kovacs, A.3
Jelliffe, R.4
Hoffman, J.5
-
10
-
-
39449117139
-
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
-
DOI 10.1086/524669
-
Pascual, A., et al. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211. (Pubitemid 351269158)
-
(2008)
Clinical Infectious Diseases
, vol.46
, Issue.2
, pp. 201-211
-
-
Pascual, A.1
Calandra, T.2
Bolay, S.3
Buclin, T.4
Bille, J.5
Marchetti, O.6
-
11
-
-
0038556830
-
Voriconazole treatment for less-common, emerging, or refractory fungal infections
-
Perfect, J. R., et al. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36:1122-1131.
-
(2003)
Clin. Infect. Dis.
, vol.36
, pp. 1122-1131
-
-
Perfect, J.R.1
-
13
-
-
42049108830
-
Therapeutic drug monitoring of antifungals: Pharmacokinetic and pharmacodynamic considerations
-
DOI 10.1097/FTD.0b013e318167d0e0, PII 0000769120080400000006
-
Smith, J., and D. Andes. 2008. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther. Drug Monit. 30:167-172. (Pubitemid 351521643)
-
(2008)
Therapeutic Drug Monitoring
, vol.30
, Issue.2
, pp. 167-172
-
-
Smith, J.1
Andes, D.2
-
14
-
-
33645761890
-
Voriconazole therapeutic drug monitoring
-
Smith, J., et al. 2006. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50:1570-1572.
-
(2006)
Antimicrob. Agents Chemother.
, vol.50
, pp. 1570-1572
-
-
Smith, J.1
-
15
-
-
77957360800
-
Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children
-
Walsh, T. J., et al. 2010. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob. Agents Chemother. 54:4116-4123.
-
(2010)
Antimicrob. Agents Chemother.
, vol.54
, pp. 4116-4123
-
-
Walsh, T.J.1
-
16
-
-
2542443542
-
Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration
-
DOI 10.1128/AAC.48.6.2166-2172.2004
-
Walsh, T. J., et al. 2004. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob. Agents Chemother. 48:2166-2172. (Pubitemid 38691615)
-
(2004)
Antimicrobial Agents and Chemotherapy
, vol.48
, Issue.6
, pp. 2166-2172
-
-
Walsh, T.J.1
Karlsson, M.O.2
Driscoll, T.3
Arguedas, A.G.4
Adamson, P.5
Saez-Llorens, X.6
Vora, A.J.7
Arrieta, A.C.8
Blumer, J.9
Lutsar, I.10
Milligan, P.11
Wood, N.12
-
17
-
-
0344512410
-
Effect of omeprazole on the steady-state pharmacokinetics of voriconazole
-
Wood, N., et al. 2003. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br. J. Clin. Pharmacol. 56(Suppl. 1):56-61. (Pubitemid 37491735)
-
(2003)
British Journal of Clinical Pharmacology, Supplement
, vol.56
, Issue.1
, pp. 56-61
-
-
Wood, N.1
Tan, K.2
Purkins, L.3
Layton, G.4
Hamlin, J.5
Kleinermans, D.6
Nichols, D.7
|